KITE-363: A phase 1 study of an autologous anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory (R/R) B-cell lymphoma (BCL).
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: The University of Texas MD Anderson Cancer Center, University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Stanford Medicine, Stanford University, University of Rochester Medicine, Banner MD Anderson Cancer Center, Kite (United States)
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4281767518